Although the immunosuppressive properties of IDO in the context of cancer are relatively well understood, whether IDO controls the responsiveness of cross-primed TCD8 targeting multiple tumor-derived epitopes and their immunodominance hierarchies remains an open and important question. This evidence concerns the gene IDO1 and cancer.